AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26170627 — intervention group
Group type: EXPERIMENTAL
Intervention: Lesinurad (general)
Number of subjects: 66
Study 24290413 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil/hydrochlorothiazide (HCTZ)
Number of subjects: 40
Study 24290413 — intervention group
Group type: EXPERIMENTAL
Intervention: HCTZ
Number of subjects: 40
Study 24290413 — intervention group
Group type: COMPARATOR
Intervention: Test and reference products
Number of subjects: 40
Study 21778269 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterochromatic flicker electroretinograms (ERGs) at 36 Hz and 12 Hz
Number of subjects: 32
Study 21778269 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterochromatic flicker electroretinograms (ERGs) at 36 Hz
Number of subjects: 32
Study 21778269 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterochromatic flicker electroretinograms (ERGs) at 12 Hz
Number of subjects: 32
Study 21778269 — intervention group
Group type: COMPARATOR
Intervention: Heterochromatic flicker electroretinograms (ERGs)
Number of subjects: 32
Study 19101249 — intervention group
Group type: EXPERIMENTAL
Intervention: Faculty-directed training
Number of subjects: 45
Study 19101249 — intervention group
Group type: COMPARATOR
Intervention: Self-directed training
Number of subjects: 45
Study 17300603 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% sodium deoxycholate (SD)
Number of subjects: 30
Study 17300603 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% sodium deoxycholate (SD)
Number of subjects: 30
Study 17300603 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 15096902 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg
Number of subjects: 96
Study 15096902 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 11779730 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (6 microM)
Number of subjects: 0
Study 11779730 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol with ascorbic acid
Number of subjects: 0
Study 11779730 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 0
Study 9821420 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-day regimen of amoxicillin/clavulanate in 3 divided doses
Number of subjects: 385
Study 9821420 — intervention group
Group type: COMPARATOR
Intervention: 10-day regimen of amoxicillin/clavulanate in 3 divided doses
Number of subjects: 385
Study 7654110 — intervention group
Group type: EXPERIMENTAL
Intervention: velnacrine maleate 150 mg/d
Number of subjects: 449
Study 7654110 — intervention group
Group type: EXPERIMENTAL
Intervention: velnacrine maleate 225 mg/d
Number of subjects: 449
Study 7654110 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 449
Study 2195978 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol (1, 2, then 3 tablets/day, adjusted according to BP)
Number of subjects: 170
Study 2195978 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine (2 tablets/day, recommended dosage)
Number of subjects: 170
Study 2195978 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 170
Study 2195978 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 170
Study 371342 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose administration
Number of subjects: 6
Study 371342 — intervention group
Group type: COMPARATOR
Intervention: Intravenous glucose administration
Number of subjects: 6
Study 31983158 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-day course of triple therapy (Rabeprazole 20 mg, Amoxicillin 1,000 mg, Clarithromycin 500 mg twice daily for 10 days plus 4 days placebo)
Number of subjects: 75
Study 31983158 — intervention group
Group type: COMPARATOR
Intervention: 14-day course of triple therapy (Rabeprazole 20 mg, Amoxicillin 1,000 mg, Clarithromycin 500 mg twice daily for 14 days)
Number of subjects: 75
Study 29750251 — intervention group
Group type: EXPERIMENTAL
Intervention: EAA + AE
Number of subjects: 50
Study 29750251 — intervention group
Group type: EXPERIMENTAL
Intervention: AE
Number of subjects: 50
Study 29750251 — intervention group
Group type: COMPARATOR
Intervention: EAA
Number of subjects: 50
Study 29750251 — intervention group
Group type: COMPARATOR
Intervention: Placebo + AE
Number of subjects: 50
Study 29750251 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 28178355 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training for 12 weeks
Number of subjects: 24
Study 28178355 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study 25666737 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior tobacco counseling experiences (at least one 5A)
Number of subjects: 1266
Study 25666737 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior tobacco counseling experiences
Number of subjects: 1266
Study 25666737 — intervention group
Group type: COMPARATOR
Intervention: No prior tobacco counseling experiences
Number of subjects: 1266
Study 24296324 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 77
Study 24296324 — intervention group
Group type: COMPARATOR
Intervention: Losartan
Number of subjects: 77
Study 21410949 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided surgery
Number of subjects: 120
Study 21410949 — intervention group
Group type: COMPARATOR
Intervention: Palpation-guided surgery
Number of subjects: 120
Study 19132203 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 80 mg daily (S80; n = 16)
Number of subjects: 32
Study 19132203 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg and Simvastatin 10 mg daily (E10/S10; n = 16)
Number of subjects: 32
Study 19132203 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 32
Study 17846352 — intervention group
Group type: EXPERIMENTAL
Intervention: Hispanic whites
Number of subjects: 32642
Study 17846352 — intervention group
Group type: EXPERIMENTAL
Intervention: Hispanic blacks
Number of subjects: 32642
Study 17846352 — intervention group
Group type: COMPARATOR
Intervention: Non-Hispanic whites
Number of subjects: 32642
Study 17846352 — intervention group
Group type: COMPARATOR
Intervention: Non-Hispanic blacks
Number of subjects: 32642
Study 17846352 — intervention group
Group type: COMPARATOR
Intervention: Hispanic whites vs Non-Hispanic whites
Number of subjects: 32642
Study 17846352 — intervention group
Group type: COMPARATOR
Intervention: Hispanic blacks vs Non-Hispanic whites
Number of subjects: 32642
Study 17846352 — intervention group
Group type: COMPARATOR
Intervention: Non-Hispanic blacks vs Non-Hispanic whites
Number of subjects: 32642
Study 15562917 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose doxycycline (20 mg, b.i.d.) for 3 months plus scaling and root planing (SRP)
Number of subjects: 30
Study 15562917 — intervention group
Group type: COMPARATOR
Intervention: Placebo (b.i.d.) for 3 months plus scaling and root planing (SRP)
Number of subjects: 30
Study 15562917 — intervention group
Group type: COMPARATOR
Intervention: Comparison between LDD and placebo groups
Number of subjects: 30
Study 11686749 — intervention group
Group type: EXPERIMENTAL
Intervention: Solution-focused brief therapy (SFBT) training
Number of subjects: 0
Study 9159625 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity oral anticoagulants (INR 2.5 to 3.5) plus aspirin (100 mg/day)
Number of subjects: 503
Study 9159625 — intervention group
Group type: COMPARATOR
Intervention: High-intensity oral anticoagulants (INR 3.5 to 4.5)
Number of subjects: 503
Study 7966259 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication placebo
Number of subjects: 0
Study 7966259 — intervention group
Group type: COMPARATOR
Intervention: Uncontrolled demand characteristics
Number of subjects: 0
Study 7966259 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled demand characteristics
Number of subjects: 0
Study 2882183 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane in 30% oxygen/70% nitrous oxide (n = 37)
Number of subjects: 71
Study 2882183 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane in 100% oxygen (n = 17)
Number of subjects: 71
Study 2882183 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane in 30% oxygen/70% nitrous oxide (n = 17)
Number of subjects: 71
Study 29430839 — intervention group
Group type: EXPERIMENTAL
Intervention: Carnosine supplementation (500 mg per day for 2 months)
Number of subjects: 43
Study 29430839 — intervention group
Group type: COMPARATOR
Intervention: Placebo (500 mg per day for 2 months)
Number of subjects: 43
Study 27240178 — intervention group
Group type: EXPERIMENTAL
Intervention: cellex
Number of subjects: 246
Study 27240178 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 246
Study 25643496 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sphincterotomy (ES)
Number of subjects: 76
Study 25643496 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic balloon dilatation (EBD)
Number of subjects: 76
Study 25643496 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined technique of ES followed by EBD
Number of subjects: 76
Study 25643496 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 76
Study 23161302 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alpha‐2a (180 μg weekly)
Number of subjects: 58
Study 23161302 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-advanced liver disease)
Number of subjects: 58
Study 23161302 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced liver disease group
Number of subjects: 58
Study 19176796 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferumoxytol (two injections of 510 mg within 7 days)
Number of subjects: 230
Study 19176796 — intervention group
Group type: COMPARATOR
Intervention: Oral iron (200 mg elemental daily for 21 days)
Number of subjects: 230
Study 19176796 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferumoxytol
Number of subjects: 230
Study 17495576 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated communication skills training program
Number of subjects: 129
Study 17495576 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 129
Study 14693624 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulation with epidural analgesia (0.08% bupivacaine‐epinephrine plus 1 microg/mL of sufentanil)
Number of subjects: 61
Study 14693624 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulation with epidural analgesia
Number of subjects: 61
Study 14693624 — intervention group
Group type: COMPARATOR
Intervention: Recumbent with epidural analgesia
Number of subjects: 61
Study 11779898 — intervention group
Group type: COMPARATOR
Intervention: N-acetylaspartate (NAA)/choline ratio in noninfarcted regions in the symptomatic hemisphere (1.73+/‐0.16)
Number of subjects: 44
Study 11779898 — intervention group
Group type: COMPARATOR
Intervention: Lactate/NAA ratio in the symptomatic hemisphere (0.04+/‐0.08)
Number of subjects: 44
Study 11779898 — intervention group
Group type: COMPARATOR
Intervention: NAA/choline ratio in both the symptomatic and asymptomatic hemispheres
Number of subjects: 44
Study 9640120 — intervention group
Group type: EXPERIMENTAL
Intervention: Premedication with diazepam alone (group 2)
Number of subjects: 45
Study 9640120 — intervention group
Group type: EXPERIMENTAL
Intervention: Premedication with diazepam and alfentanil (group 3)
Number of subjects: 45
Study 9640120 — intervention group
Group type: COMPARATOR
Intervention: No premedication (group 1)
Number of subjects: 45
Study 7978521 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical headgear/tandem mechanics
Number of subjects: 190
Study 7978521 — intervention group
Group type: EXPERIMENTAL
Intervention: Bionator appliance
Number of subjects: 190
Study 7978521 — intervention group
Group type: COMPARATOR
Intervention: Control group (Bolton Study)
Number of subjects: 190
Study 2556727 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous alprazolam
Number of subjects: 0
Study 2556727 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 5134998 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimethyltriazeno imidazole carboxamide, 2.0 mg/kg for 10 days
Number of subjects: 155
Study 5134998 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimethyltriazeno imidazole carboxamide, 4.5 mg/kg for 10 days
Number of subjects: 155
Study 31785626 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-cervical artificial insemination (PCAI; 1.5 × 10^9 spermatozoa/45 mL)
Number of subjects: 644
Study 31785626 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-cervical artificial insemination (PCAI)
Number of subjects: 644
Study 31785626 — intervention group
Group type: COMPARATOR
Intervention: Cervical artificial insemination (CAI; 3 × 10^9 spermatozoa/90 mL)
Number of subjects: 644
Study 28292775 — intervention group
Group type: EXPERIMENTAL
Intervention: PPV with ILM peeling combined with macular buckle under direct vision (group 2, n=46)
Number of subjects: 98
Study 28292775 — intervention group
Group type: COMPARATOR
Intervention: PPV with ILM peeling (group 1, n=52)
Number of subjects: 98
Study 27442000 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous radiofrequency thermocoagulation denervation on the lumbar facet joint
Number of subjects: 80
Study 27442000 — intervention group
Group type: COMPARATOR
Intervention: Injection of betamethasone and lidocaine into the lumbar facet joint
Number of subjects: 80
Study 25118962 — intervention group
Group type: EXPERIMENTAL
Intervention: Bushen Yiqi (BY) granule
Number of subjects: 331
Study 25118962 — intervention group
Group type: EXPERIMENTAL
Intervention: Bushen Fangchuan (BF) tablet
Number of subjects: 331
Study 25118962 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 331
Study 22238571 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased cerebro-cerebral coherence between contralateral M1 and SMA during movement preparation and execution in GTS patients
Number of subjects: 20
Study 22238571 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 20
Study 21034892 — intervention group
Group type: EXPERIMENTAL
Intervention: Covered stent
Number of subjects: 400
Study 21034892 — intervention group
Group type: COMPARATOR
Intervention: Uncovered stent
Number of subjects: 400
Study 17522246 — intervention group
Group type: EXPERIMENTAL
Intervention: BSC plus panitumumab, 6 mg/kg i.v., every other week
Number of subjects: 463
Study 17522246 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care (BSC) alone
Number of subjects: 463
Study 15855226 — intervention group
Group type: EXPERIMENTAL
Intervention: IRI/LV/5‐FU
Number of subjects: 295
Study 15855226 — intervention group
Group type: COMPARATOR
Intervention: OXA/LV/5‐FU
Number of subjects: 295
Study 11955909 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser in situ keratomileusis (LASIK)
Number of subjects: 59
Study 9802454 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori eradication in patients with DU
Number of subjects: 103
Study 9802454 — intervention group
Group type: COMPARATOR
Intervention: H. pylori-positive patients with DU
Number of subjects: 103
Study 9802454 — intervention group
Group type: COMPARATOR
Intervention: H. pylori-negative patients with DU
Number of subjects: 103
Study 8583263 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-generated feedback to physicians about the patient's functional status and educational sessions for physicians
Number of subjects: 557
Study 2669935 — intervention group
Group type: EXPERIMENTAL
Intervention: Bed-rest in hospital
Number of subjects: 139
Study 2669935 — intervention group
Group type: COMPARATOR
Intervention: Conventional outpatient management
Number of subjects: 139
Study 837962 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxantrazole 200 mg taken orally 1 hour before exercise test
Number of subjects: 13
Study 837962 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxantrazole 400 mg taken orally
Number of subjects: 13
Study 31805571 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin (TAM) + Serenoa repens (SR) 320 mg/day + Bovine Colostrum (BC) 30 mg/day
Number of subjects: 148
Study 31805571 — intervention group
Group type: COMPARATOR
Intervention: Tamsulosin (TAM) only
Number of subjects: 148
Study 31805571 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin (TAM) + Serenoa repens (SR) + Bovine Colostrum (BC)
Number of subjects: 148
Study 31060549 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized aqueous extract of Phyllanthus emblica (P. emblica) 250 mg twice daily
Number of subjects: 59
Study 31060549 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized aqueous extract of Phyllanthus emblica (P. emblica) 500 mg twice daily
Number of subjects: 59
Study 28928175 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated AF management involving a trained practice nurse and collaboration with secondary care
Number of subjects: 1000
Study 28928175 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 1000
Study 25769436 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural cocoa consumption (12.7 g natural cocoa, 148 kcal/serving) for 4 weeks
Number of subjects: 24
Study 25769436 — intervention group
Group type: COMPARATOR
Intervention: Cocoa-free placebo for 4 weeks
Number of subjects: 24
Study 23826659 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT)
Number of subjects: 170
Study 23826659 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurohormonal response
Number of subjects: 170
Study 22156664 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil Protect Bond (PB; Kuraray Medical)
Number of subjects: 52
Study 22156664 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond (SE; Kuraray Medical)
Number of subjects: 52
Study 22156664 — intervention group
Group type: EXPERIMENTAL
Intervention: Both primers (PB and SE)
Number of subjects: 52
Study 19573330 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffractive multifocal intraocular lens
Number of subjects: 65
Study 19573330 — intervention group
Group type: COMPARATOR
Intervention: Monofocal intraocular lens
Number of subjects: 65
Study 17893628 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactulose
Number of subjects: 308
Study 17893628 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethylene glycol
Number of subjects: 308
Study 17893628 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 308
Study 17893628 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 308
Study 17893628 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine administration
Number of subjects: 308
Study 14959818 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% Supplemental Oxygen (SuppO2)
Number of subjects: 70
Study 14959818 — intervention group
Group type: COMPARATOR
Intervention: Compressed Air (CA)
Number of subjects: 70
Study 11575487 — intervention group
Group type: EXPERIMENTAL
Intervention: Search version of medical scenarios (information pursued after some information was missing)
Number of subjects: 1206
Study 11575487 — intervention group
Group type: COMPARATOR
Intervention: Simple version of medical scenarios (information received from the start)
Number of subjects: 1206
Study 9640556 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunscreen preparations containing protective ingredients (dimethicone and cyclomethicone)
Number of subjects: 0
Study 9640556 — intervention group
Group type: COMPARATOR
Intervention: Sunscreen preparations without protective ingredients
Number of subjects: 0
Study 7527592 — intervention group
Group type: EXPERIMENTAL
Intervention: ifosfamide/carboplatin/etoposide (ICE)
Number of subjects: 115
Study 7527592 — intervention group
Group type: EXPERIMENTAL
Intervention: Hematopoietic growth factor administration
Number of subjects: 115
Study 7527592 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor
Number of subjects: 115
Study 7527592 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral blood stem cells primed with cyclophosphamide and granulocyte colony-stimulating factor
Number of subjects: 115
Study 7527592 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet recovery
Number of subjects: 115
Study 3052065 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid treatment
Number of subjects: 0
Study 3052065 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study 31219315 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed tomography
Number of subjects: 68
Study 31219315 — intervention group
Group type: COMPARATOR
Intervention: Standard care (serial examination with or without ultrasound)
Number of subjects: 68
Study 28893866 — intervention group
Group type: EXPERIMENTAL
Intervention: FK506 (tacrolimus) therapy with target levels <2, 2-3, and 3-5 ng·mL-1
Number of subjects: 23
Study 28893866 — intervention group
Group type: EXPERIMENTAL
Intervention: FK506 (tacrolimus) therapy
Number of subjects: 23
Study 28893866 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 26265421 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week walking/running aerobic exercise program
Number of subjects: 46
Study 26265421 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (Control)
Number of subjects: 46
Study 22538374 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-tone AXB paradigm with varying intensity levels of tone X (closer to Tone A or B)
Number of subjects: 0
Study 22538374 — intervention group
Group type: COMPARATOR
Intervention: Preceding AXB patterns with null intensity context sequences
Number of subjects: 0
Study 22538374 — intervention group
Group type: COMPARATOR
Intervention: Preceding AXB patterns with coherent intensity context sequences
Number of subjects: 0
Study 21257115 — intervention group
Group type: EXPERIMENTAL
Intervention: Early adolescence depressive symptoms
Number of subjects: 678
Study 21257115 — intervention group
Group type: EXPERIMENTAL
Intervention: High depressive symptoms with increases in impulsivity
Number of subjects: 678
Study 21257115 — intervention group
Group type: EXPERIMENTAL
Intervention: High impulsivity with increases in depressive symptoms
Number of subjects: 678
Study 21257115 — intervention group
Group type: COMPARATOR
Intervention: Nongamblers and social gamblers
Number of subjects: 678
Study 19920417 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5% (150 mg)
Number of subjects: 86
Study 19920417 — intervention group
Group type: COMPARATOR
Intervention: Levobupivacaine 0.33% (99 mg)
Number of subjects: 86
Study 17047644 — intervention group
Group type: COMPARATOR
Intervention: Three courses of carboplatin (AUC 4) and vinorelbine (25 mg/m²)
Number of subjects: 297